Hemorrhagic disease
MONDO:0002243Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (blood coagulation disorders) or another abnormality causing a structural flaw in the blood vessels (hemostatic disorders).
Also known as: bleeding diathesis, bleeding disorder, bleeding predisposition, bleeding tendency
492 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Clotting drug may replace plasma transfusions in heart surgery
Disease control TerminatedThis study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …
Phase: PHASE4 • Sponsor: SHI Jia • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control TerminatedThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Phase: PHASE1, PHASE2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Aspirin study for kidney patients halted early – did the risks outweigh the benefits?
Disease control TerminatedThis study looked at whether taking a daily low-dose aspirin could help people with chronic kidney disease avoid their first heart attack or stroke. Over 4,600 participants were randomly assigned to take aspirin or receive usual care. The trial was stopped early, and the final re…
Phase: PHASE3 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Tailored drug regimen shows promise for rare blood disorder
Disease control TerminatedThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase: PHASE2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hemophilia drug study falls short: only 3 patients enrolled before termination
Disease control TerminatedThis study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can extra care after transplant help older patients live better?
Disease control TerminatedThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Bleeding breakthrough fizzles: fibrinogen trial for chemo patients halted after just one patient
Disease control TerminatedThis study tested a single injection of fibrinogen concentrate followed by a platelet transfusion in blood cancer patients with severe bleeding who did not respond to standard platelet transfusions. The goal was to see if it improved blood clotting. However, the trial was termina…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control TerminatedThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising FNAIT prevention study halted early after just one participant
Prevention TerminatedThis study tested a drug called RLYB212 in pregnant women at high risk for a condition where the mother's immune system attacks the baby's platelets, causing dangerous bleeding. The goal was to see if the drug was safe and how it moved through the body. Only one woman enrolled be…
Phase: PHASE2 • Sponsor: Rallybio • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
Could home blood tests transform hemophilia care? study seeks patient views
Knowledge-focused TerminatedThis study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC